Sign in

    Matthew Miksic • Barclays

    Matthew Miksic's questions to Medtronic PLC (MDT) leadership

    Matthew Miksic's questions to Medtronic PLC (MDT) leadership • Q4 2025

    Question

    Matthew Miksic sought clarification on the components of the guided 7% operating profit growth and asked for color on the Spine business's above-market performance and confidence in tariff mitigations.

    Answer

    CFO Thierry Pieton confirmed the 7% operating profit growth is ex-tariffs and includes planned investments. CEO Geoffrey Martha and Executive Brett Wall attributed the Spine division's strength to its differentiated AiBLE ecosystem, which integrates robotics, navigation, and AI planning. They noted this technological lead is driving share gains, attracting top sales talent, and winning key academic centers.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Medtronic PLC (MDT) leadership • Q4 2025

    Question

    Matthew Miksic sought clarification on the FY26 operating profit growth guidance and asked for color on the Spine business's above-market performance and the factors driving its success.

    Answer

    CEO Geoff Martha and EVP Brett Wall attributed the Spine division's strength to its differentiated AiBLE ecosystem, which integrates robotics, navigation, and AI planning. They noted this comprehensive solution is driving share gains, attracting top academic centers, and creating a durable competitive advantage as competitors struggle to match the required investment.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Medtronic PLC (MDT) leadership • Q3 2025

    Question

    Matthew Miksic from Barclays asked about the performance of the Peripheral Vascular business, which saw a low-single-digit decline, and inquired about the confidence and timing for its recovery.

    Answer

    CEO Geoff Martha directly attributed the softness in the Peripheral Vascular business to a Volume-Based Procurement (VBP) issue in China. He stated that while Medtronic has worked through most of its VBP challenges, some volatility remains in specific business lines, which impacted PV this quarter, but he expects it to work its way out.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Medtronic PLC (MDT) leadership • Q2 2025

    Question

    Matthew Miksic sought clarification on several key topics, including the launch timing for Affera in the U.S., the timeline for an RDN national coverage decision, the status of the diabetes patch pump, and the mechanics of the back-half EPS growth and FX impact.

    Answer

    Chairman and CEO Geoff Martha stated that while they are not providing specific timelines, Affera is ramping and contributing to strong PFA growth, RDN coverage timing is difficult to predict, and the diabetes patch program has multiple 'shots on goal.' Interim CFO Gary Corona confirmed the FX headwind is about $0.10 in the second half and reiterated that the company's hedging program and operational initiatives are mitigating its impact.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Globus Medical Inc (GMED) leadership

    Matthew Miksic's questions to Globus Medical Inc (GMED) leadership • Q1 2025

    Question

    Matthew Miksic asked for management's confidence in a Q2 recovery after a soft Q1, questioning which headwinds were temporary versus those requiring more effort, and also inquired about the synergy realization plan for the Nevro acquisition.

    Answer

    CEO Dan Scavilla characterized the Q1 softness as a 'blip' caused by temporary supply chain disruptions and an elongated capital sales cycle, expressing confidence in a Q2 recovery based on strong early trends. COO and CFO Keith Pfeil added that for Nevro, the immediate synergy focus is on reducing operational expenses, particularly its high SG&A, to drive profitability.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Globus Medical Inc (GMED) leadership • Q4 2024

    Question

    Matthew Miksic from Barclays asked for context on the investment level required for the Nevro acquisition and inquired about the penetration depth of robot deals within the legacy NuVasive customer base.

    Answer

    President and CEO Dan Scavilla and CFO Keith Pfeil clarified that the Nevro investment would not cause a meaningful shift in the company's P&L, staying within the 6-7% R&D spending range. Scavilla noted that penetration of robotic systems into the NuVasive base is just beginning, suggesting significant runway for growth in 2025. Pfeil added that the capital sales cadence is expected to remain strongest in Q2 and Q4.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Globus Medical Inc (GMED) leadership • Q3 2024

    Question

    Matthew Miksic of Barclays inquired about the primary drivers for the significant EBITDA margin improvement and the progress of integrating the NuVasive sales force to sell Globus's robotic systems.

    Answer

    COO & CFO Keith Pfeil attributed the margin strength to aggressive cost redundancy elimination and facility consolidation, focusing on tangible cash savings. President & CEO Dan Scavilla explained that progress with the NuVasive sales force involves extensive training and getting NuVasive's implant products approved for use with the robotic software, which is a key focus for 2025.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Inmode Ltd (INMD) leadership

    Matthew Miksic's questions to Inmode Ltd (INMD) leadership • Q1 2025

    Question

    Matthew Miksic from Jefferies, along with colleague Matthew Taylor, inquired about the drivers behind the updated guidance, specifically the impact of product and geographic mix, the rationale for holding guidance despite a Q1 shortfall, the expected quarterly phasing for the year, the financial impact of new tariffs, and the contribution of new products to the forecast.

    Answer

    CEO Moshe Mizrahy and CFO Yair Malca explained that the slowdown, which began in mid-2023, is driven by high interest rates impacting equipment financing and lower consumer confidence deferring procedures. They noted a significant geographic mix shift, with the U.S. falling to 50% of revenue from a historical 62-63%. Management is holding the full-year guidance optimistically, pending Q2 results; if Q2 revenue is not above $100 million, guidance will be lowered. Moshe Mizrahy detailed that a 10% tariff would impact gross margins by 2-3% but stated new products are not expected to drive incremental growth in a down market.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Inmode Ltd (INMD) leadership • Q4 2024

    Question

    Matthew Miksic asked for an update on the management structure changes implemented in the fall and how they are proceeding. He also requested insight into the expected cadence of a business recovery, specifically the relationship between patient flow and subsequent system demand.

    Answer

    CEO Moshe Mizrahy detailed the management changes, including new leadership in three European countries, a new VP role overseeing European subsidiaries, and two new VPs of Sales in the U.S., where he is currently acting President of North America. On the recovery cadence, he explained that a turnaround depends on two factors: a decrease in equipment leasing interest rates and a rebound in patient demand for procedures, which the company monitors through sales of disposables.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Inmode Ltd (INMD) leadership • Q3 2024

    Question

    Matthew Miksic asked how InMode maintained its full-year EPS guidance despite a revenue guidance reduction, questioning where cost controls were implemented. He also inquired about the potential timing for a market recovery in the U.S.

    Answer

    CEO Moshe Mizrahy clarified that no significant cost-cutting measures were taken in Q3; in fact, manufacturing costs increased slightly due to overtime work in Israel. He attributed the stable profitability to the company's inherent financial structure. Regarding a market recovery, Mizrahy stated that the slowdown persists, with no improvement seen in leasing interest rates, and he is hesitant to predict a turnaround timeline, though he hopes for one in 2025.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Dexcom Inc (DXCM) leadership

    Matthew Miksic's questions to Dexcom Inc (DXCM) leadership • Q1 2025

    Question

    Matthew Miksic from Barclays asked how the role of Stelo has evolved and how it fits together with G7, especially now that G7 has broader coverage in the non-insulin market.

    Answer

    CEO Kevin Sayer and COO Jacob Leach explained Stelo's dual role. Sayer noted it gives the sales force an option for physicians to offer patients who lack G7 coverage. Leach added that Stelo is also being expanded beyond diabetes into the health and wellness space with new features and partnerships like the Oura integration.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Dexcom Inc (DXCM) leadership • Q4 2024

    Question

    Matthew Miksic asked for a timeline on the G8 sensor and questioned the perception of lower economic value from less acute patients, seeking to understand the real-world dynamics.

    Answer

    CEO Kevin Sayer declined to provide a G8 timeline, stating the current focus is on the G7 15-day launch. On patient economics, he and CFO Jereme Sylvain clarified that while utilization per patient per year may be slightly lower in less acute populations, the price per sensor is the same. For reimbursed patients, utilization remains high, and therefore the per-transaction margins are not impacted.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Stryker Corp (SYK) leadership

    Matthew Miksic's questions to Stryker Corp (SYK) leadership • Q1 2025

    Question

    Matthew Miksic asked about conversations with hospitals regarding their budgets and for details on the key drivers of Stryker's strong growth in the shoulder market.

    Answer

    VP Jason Beach confirmed that the hospital capital environment is positive, with hospitals doing well and Stryker's capital businesses growing double-digits. CEO Kevin Lobo detailed that shoulder growth is driven by a comprehensive portfolio including the modern Perform system, patient-specific implants, a novel pyrocarbon product, and the AI-powered Blueprint planning software.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Stryker Corp (SYK) leadership • Q4 2024

    Question

    Matthew Miksic asked about the growth sustainability of businesses with recent major product launches, like the 1788 camera and LIFEPAK 35. He also inquired about the contribution of non-robotic enabling technologies, such as Blueprint software, to the shoulder business.

    Answer

    CEO Kevin Lobo expressed confidence that growth in these areas is sustainable, as the R&D pipeline is timed to introduce new products before current ones slow. He highlighted that the shoulder business's success is built on an ecosystem of market-leading implants and the Blueprint planning software, which is now integrated with Mako.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Stryker Corp (SYK) leadership • Q3 2024

    Question

    Matthew Miksic asked for clarification on the Mako leasing mix between the U.S. and international markets, and for color on the percentage of new Mako installations going into Ambulatory Surgery Centers (ASCs).

    Answer

    CFO Glenn Boehnlein confirmed that Mako leasing and rental agreements are more common in the U.S. compared to outside the U.S. CEO Kevin Lobo deferred providing a specific percentage for ASC installations until the year-end update but confirmed that the trend of placements in ASCs is increasing as part of their successful ASC strategy.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Alphatec Holdings Inc (ATEC) leadership

    Matthew Miksic's questions to Alphatec Holdings Inc (ATEC) leadership • Q1 2025

    Question

    Matthew Miksic requested more color on cash flow trends for the remainder of the year and inquired about the competitive dynamics related to recruiting sales representatives.

    Answer

    Executive Patrick Miles highlighted improving instrument set utilization as a key driver of cash efficiency. Executive J. Koning provided a specific cash flow outlook: $0 to +$5 million in Q2, followed by positive cash flow in Q3 and Q4, achieving full-year positivity. Regarding recruitment, Miles described ATEC as the 'preferred destination' for spine specialists, noting success in attracting talent from competitors like Stryker, Medtronic, and Globus due to ATEC's pure-play focus.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Alphatec Holdings Inc (ATEC) leadership • Q4 2024

    Question

    Matthew Miksic asked how the 2024 strategy for share capture and sales team upgrades contributed to year-end strength, how ATEC competes without a robot, and how the upcoming robot launch could enhance growth. He also followed up on the opportunity presented by the Stryker/K2M transition in academic centers.

    Answer

    Patrick Miles (Executive) explained that while the sales force is improving, significant geographic gaps remain, representing a long growth runway. He positioned ATEC's informatics-led approach (EOS) as a more comprehensive solution to spine surgery's core issues than robotics alone. He also confirmed the opportunity in pediatric surgery via the EOS footprint is significant but in very early stages. J. Koning (Executive) added that recent investments in instruments and inventory position them well to capitalize on market disruption.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Alphatec Holdings Inc (ATEC) leadership • Q3 2024

    Question

    Matthew Miksic asked why not having a robot today is not a competitive disadvantage and inquired about the company's confidence in its EBITDA and cash deployment guidance.

    Answer

    Executive Patrick Miles explained that ATEC's strategy prioritizes the most significant variables in spine care, starting with information and decision-making via its EOS imaging ecosystem, which he views as more foundational than robotics for screw placement. Executive J. Koning reaffirmed confidence in financial targets, noting that inventory inefficiencies from earlier in the year will support future growth, reducing the need for new investment and keeping the company on its planned path to cash flow breakeven.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Becton Dickinson and Co (BDX) leadership

    Matthew Miksic's questions to Becton Dickinson and Co (BDX) leadership • Q2 2025

    Question

    Matthew Miksic asked a dual question about the runway for cost optimization programs, given their past success, and what specific actions the company is taking to leverage AI for internal efficiencies and value creation.

    Answer

    Chairman, CEO and President Thomas Polen stated that lessons from navigating hyperinflation are being applied to the current tariff environment. On AI, he described a prudent approach of piloting and confirming value before scaling. He cited AI applications in new products like APM and Pyxis Pro, as well as for internal processes like automated expense reviews, manufacturing line scheduling, and inventory management. CFO Christopher DelOrefice added that these initiatives free up capital for reinvestment in selling and R&D.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Becton Dickinson and Co (BDX) leadership • Q1 2025

    Question

    Matthew Miksic inquired about the process leading to the separation announcement and the key factors that will ultimately drive the decision between the various potential transaction structures like a sale, spin-off, or Reverse Morris Trust.

    Answer

    Chairman, CEO and President Tom Polen reiterated that the company will share more details on the final form of the transaction by the end of fiscal 2025. He emphasized that the primary decision-making criterion is selecting the transaction structure that maximizes shareholder value creation, and the company believes multiple paths exist to achieve this goal.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Becton Dickinson and Co (BDX) leadership • Q4 2024

    Question

    Matthew Miksic asked for more detail on BD's strategy in Artificial Intelligence, including specific products, how the company is leveraging its vast data, and how AI is fueling its broader strategies.

    Answer

    Chairman, CEO, and President Tom Polen detailed BD's existing AI applications in microbiology and narcotic diversion detection. He highlighted the future potential of integrating the newly acquired APM business's predictive algorithms with Alaris pumps to create closed-loop systems. He also previewed a new cross-device AI platform launching with the next-gen Pyxis system, fueled by data from millions of smart devices and increased R&D investment.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Tandem Diabetes Care Inc (TNDM) leadership

    Matthew Miksic's questions to Tandem Diabetes Care Inc (TNDM) leadership • Q1 2025

    Question

    Matthew Miksic asked for an update on the company's salesforce expansion and realignment, inquiring if any disruptive issues from Q4 2024 have moderated.

    Answer

    CEO John Sheridan clarified that there were no disruptive events in Q4, only hiring. He stated the salesforce expansion and territory realignment are now complete, with new hires expected to take 9-12 months to reach full productivity, positioning them to contribute significantly by Q4 2025.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Tandem Diabetes Care Inc (TNDM) leadership • Q4 2024

    Question

    Matthew Miksic of Barclays asked about the new product innovations included in the 2025 guidance and inquired about the development and regulatory pathway for the Sigi patch pump, including whether it would require a large clinical trial.

    Answer

    John Sheridan, President and CEO, detailed the 2025 pipeline, including Control-IQ+, FreeStyle Libre 3 integration, and an Android app for Mobi. Regarding Sigi, he explained it will be an ACE (interoperable) pump, which allows it to use already-approved algorithms like Control-IQ, thus not requiring a new large trial for the algorithm itself.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Tandem Diabetes Care Inc (TNDM) leadership • Q3 2024

    Question

    Matthew Miksic asked about the development of the Mobi: Tubeless cartridge and whether it could be integrated with the longer-wear Steadiset technology.

    Answer

    President and CEO John Sheridan expressed excitement about the progress of Mobi: Tubeless and confirmed that integrating longer-wear set technology is a definite option they are considering. He also clarified that the current 3-day FDA filing for Steadiset is a risk-mitigation strategy to streamline the future submission for the 7-day set.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Bausch + Lomb Corp (BLCO) leadership

    Matthew Miksic's questions to Bausch + Lomb Corp (BLCO) leadership • Q1 2025

    Question

    Matthew Miksic asked about the broader strategy for the Surgical business beyond IOLs, including equipment and next-generation lenses. He also inquired about the company's M&A posture and how the current uncertain environment is affecting its deal-making activity.

    Answer

    Chairman and CEO Brenton L. Saunders and Head of R&D Yehia Hashad highlighted multiple initiatives, including an anticipated MIGS device approval by year-end, a new Stellaris system (seeNOVA) in late 2026, and the European launch of LuxSmart/LuxLife IOLs. On M&A, Saunders stated that while the market has slowed due to uncertainty, Bausch + Lomb is not planning any large deals this year. Instead, the focus is on acquiring IP and early-stage technologies, benefiting from a slowdown in venture funding.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Bausch + Lomb Corp (BLCO) leadership • Q4 2024

    Question

    Matthew Miksic sought clarification on the 2025 growth guidance versus recent double-digit performance, and asked about the Surgical business, specifically what key gaps remain in the portfolio that the company aims to close to enhance its competitive position.

    Answer

    Chairman and CEO Brenton L. Saunders addressed the surgical question, stating that the strategy is to drive into the premium category, which is just beginning with recent launches like Envy. He believes the IOL portfolio is comprehensive and becoming more so with products like LuxLife and enVista Beyond in the pipeline. He mentioned the game-changing potential of Elios for glaucoma and early development of an adjustable IOL, concluding he sees no significant near-term gaps. CFO Osama Eldessouky reiterated that the guidance reflects growing above market while absorbing headwinds from the IRA and market access investments.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Bausch + Lomb Corp (BLCO) leadership • Q3 2024

    Question

    Matthew Miksic asked about the expected timing of the impact from the new DTC campaigns for Xiidra and Miebo, and the clinical messaging to physicians on how to use these two products together.

    Answer

    CEO Brenton L. Saunders noted that the Xiidra DTC campaign has already correlated with positive TRx growth, while it is too early to measure the impact of the two-week-old Miebo campaign. He explained the clinical messaging positions Xiidra as the best-in-class anti-inflammatory and Miebo as the only approved anti-evaporative option, providing physicians with a comprehensive toolkit for all types of dry eye disease.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Boston Scientific Corp (BSX) leadership

    Matthew Miksic's questions to Boston Scientific Corp (BSX) leadership • Q1 2025

    Question

    Matthew Miksic of Barclays asked about the future potential of recent acquisitions under Boston Scientific's management and inquired about other strategic areas where the company continues to see investment opportunities.

    Answer

    Michael Mahoney, Chairman and CEO, confirmed the company will remain very active in M&A to widen its category leadership. He expressed bullishness on the integration and future growth of Relievant and Axonics, and highlighted recent deals like Bolt (IVL) and Antero (Oncology). He also underscored the strategic importance of the company's venture fund as a consistent source of future acquisition growth.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Boston Scientific Corp (BSX) leadership • Q3 2024

    Question

    Matthew Miksic from Barclays asked about the dynamics in the gross margin line, including the Q3 FX headwind, and the sources of operating leverage moving into 2025.

    Answer

    CFO Dan Brennan explained that the Q3 gross margin of 70.4% was slightly below expectations primarily due to foreign exchange. He reiterated that while 2024 gross margin will be below 2023, the company is still driving operating margin expansion through SG&A leverage. For 2025 and beyond, he expects gross margin to be a contributor to operating margin improvement, driven by favorable product mix as FARAPULSE and WATCHMAN sales grow.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Johnson & Johnson (JNJ) leadership

    Matthew Miksic's questions to Johnson & Johnson (JNJ) leadership • Q1 2025

    Question

    Matthew Miksic of Barclays asked about the portfolio strategy for TREMFYA and the oral icotrokinra in immunology, and also sought clarification on whether the underlying orthopedics growth was below market.

    Answer

    CFO Joseph Wolk confirmed that the orthopedics performance was slightly below market and that the company needs to improve. On immunology, EVP Jennifer Taubert highlighted TREMFYA's strong IBD launch, while EVP John Reed positioned icotrokinra as a market expansion opportunity, offering a pill with biologic-like efficacy. Management sees both as key future growth drivers.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to LivaNova PLC (LIVN) leadership

    Matthew Miksic's questions to LivaNova PLC (LIVN) leadership • Q4 2024

    Question

    Matthew Miksic of Barclays sought more detail on the OUS epilepsy business, asking if the guided return to high single-digit growth would be achieved by mid-year. He also asked about the Cardiopulmonary business, questioning if management's confidence in the sustainability of high single-digit growth has increased, suggesting it may be more permanent than a temporary swell.

    Answer

    CEO Vladimir Makatsaria stated that the recovery in OUS epilepsy is expected to be well-balanced throughout the year, not just a gradual ramp, with a return to high single-digit growth. On Cardiopulmonary, Makatsaria confirmed his confidence in sustainable growth has significantly increased. He cited healthy procedure growth, strong pricing, the Essenz upgrade cycle (projected to go from 40% of units in 2024 to 60% in 2025), and durable market share gains in disposables, supported by ongoing capacity expansion.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to LivaNova PLC (LIVN) leadership • Q3 2024

    Question

    Matthew Miksic asked about the P&L puts and takes for 2025 related to the DTD and OSA programs, depending on future decisions. He also requested specific figures for the baseline investment levels for both programs.

    Answer

    CFO Alex Shvartsburg explained that DTD investment will remain at a 'bare minimum' until a positive CMS signal, while the OSA decision gate is PMA approval, with multiple commercialization options available. Chief Innovation Officer Ahmet Tezel specified the 2025 DTD investment is planned at around $10 million. CEO Vladimir Makatsaria added that any significant OSA commercialization spend would likely be a 2026 event, not 2025.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Baxter International Inc (BAX) leadership

    Matthew Miksic's questions to Baxter International Inc (BAX) leadership • Q4 2024

    Question

    Matthew Miksic inquired about the current capital equipment environment, specifically concerning demand cycles and sector trends for patient support systems like beds sold to hospitals.

    Answer

    Executive Joel Grade described the capital environment as "quite good," noting a 15% year-over-year growth in U.S. capital orders for Care and Connectivity Solutions (CCS) in 2024 and a healthy backlog heading into 2025. An executive identified as Brent added that these positive results are also due to significant improvements within the U.S. commercial organization and increased rigor in their processes.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Edwards Lifesciences Corp (EW) leadership

    Matthew Miksic's questions to Edwards Lifesciences Corp (EW) leadership • Q4 2024

    Question

    Matt Miksic asked about the potential number of centers that could ultimately adopt the EVOQUE procedure, comparing it to the TAVR center universe. He also inquired about the company's strategy for mitigating early launch challenges like patient identification, procedure times, and training.

    Answer

    Daveen Chopra, Global Leader of TMTT, suggested the upper bound for EVOQUE centers is the ~850 existing structural heart programs but emphasized a gradual, linear rollout. He described the early launch challenges as typical for a new therapy, expecting efficiencies in procedure time and patient referrals to improve over time as physicians gain experience and positive clinical results become more widely known, similar to the adoption curves of TAVR and mitral therapies.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Edwards Lifesciences Corp (EW) leadership • Q3 2024

    Question

    Matthew Miksic asked for clarification on the gross margin outlook for Q4 and 2025, following the detailed commentary provided on operating margins.

    Answer

    CFO Scott Ullem stated that the Q4 gross margin is expected to be at the high end of the original 76% to 78% full-year guidance range. He added that this level is also a reasonable preliminary modeling assumption for 2025, while noting it is subject to factors like foreign exchange rates.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Zimmer Biomet Holdings Inc (ZBH) leadership

    Matthew Miksic's questions to Zimmer Biomet Holdings Inc (ZBH) leadership • Q4 2024

    Question

    Matthew Miksic from Barclays inquired about the Paragon 28 acquisition, focusing on the integration of its independent sales force and the strategy for its total ankle portfolio.

    Answer

    President and CEO Ivan Tornos described the integration as "as simple as it gets." He explained that ZBH is experienced with exclusive 1099 sales forces and is committed to retaining the Paragon 28 team, noting there is no channel conflict. He also clarified the acquisition is broad, covering multiple foot and ankle categories beyond total ankle, and he sees no reason for disruption in that specific product line.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Insulet Corp (PODD) leadership

    Matthew Miksic's questions to Insulet Corp (PODD) leadership • Q3 2024

    Question

    Matthew Miksic asked how Insulet measures its customer retention rate and requested color on how that metric has been trending.

    Answer

    President and CEO Jim Hollingshead explained that the cloud-connected nature of Omnipod 5 provides very high-fidelity data to track user starts and stops. He stated that the retention rate is 'really high' and 'very stable,' running in the 'low 90s' and does not fluctuate significantly from period to period.

    Ask Fintool Equity Research AI

    Matthew Miksic's questions to Intuitive Surgical Inc (ISRG) leadership

    Matthew Miksic's questions to Intuitive Surgical Inc (ISRG) leadership • Q3 2024

    Question

    Matthew Miksic asked for a big-picture view on U.S. procedure growth drivers over the next few years, questioning whether growth will come more from deeper penetration into existing procedures or from expansion into new, large segments.

    Answer

    CEO Gary Guthart described the U.S. strategy as a 'balanced perspective.' He explained that for some mature procedures, the focus is on driving depth and reaching surgeons who have not yet fully adopted the technology. Simultaneously, the company is actively seeking new opportunities and patient populations, particularly through new indications for Ion and SP, and more niche indications for the multiport platform. He indicated more details on new opportunities would be shared as they mature.

    Ask Fintool Equity Research AI